Combination Therapy for Alcohol Use Disorder
NCT07249554 on ClinicalTrials.gov · last registry update 2026-10-01
A small phase 2 — 45 participants, against a typical 110. Due to report July 2028, alongside 23 other tracked readouts that quarter. Primary outcome, as filed: Participant-reported Adverse Events. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for alcohol use disorder — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- NOT_YET_RECRUITING
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Johns Hopkins University
- Sponsor type
- Other
- Enrollment
- 45
- Started
- 2026-11
- Primary completion
- 2028-07 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Participant-reported Adverse Events
Conditions studied
Alcohol Use Disorder
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.